Prognosis
Pfizer, BioNTech Vaccine Trial Remains on Track, CEO Says
- Partners haven’t had to stop late-stage study on safety issues
- They could potentially be first to show if a Covid shot works
This article is for subscribers only.
Side effects that have emerged in a large late-stage trial of a Covid-19 vaccine candidate from Pfizer Inc. and BioNTech SE are in line with those seen in smaller early studies, a positive sign for one of the front-runners in the race for a shot.
The partners haven’t had to stop their late-stage study over safety concerns, BioNTech Chief Executive Officer Ugur Sahin said in an interview. They’re sticking with their previously announced target of being able to provide preliminary data on whether the vaccine works as soon as this month, if a threshold for infections is reached; if so, any submissions for regulatory approval would come later.